ORMP Oramed: Enterprise Value to EBITDA Ratio
Oramed Pharmaceuticals (ORMP) adheres to basic environmental standards, focusing on laboratory testing and proper waste disposal. The business relies on breakthrough biochemistry that replaces insulin injections with convenient tablets. This chart reflects an asset value of 0.00, which complements data regarding the creation of automated dosing and packaging systems to reduce manual labor costs.
Comprehensive metric breakdowns and analytics for oramed.com (ORMP)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Oramed Pharmaceuticals|ORMP - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Oramed Pharmaceuticals Inc.|ORMP - Company Cumulative Debt|Debt to Book Capitalization Ratio ORMP|ORMP - Company Long-Term Loans and Borrowings|Company Short-Term Debts Oramed Pharmaceuticals|Quick Liquidity oramed.com
- financial results and valuation multiples details:
ORMP - Net Income|Projected Future Earnings Oramed Pharmaceuticals|ORMP - Market Cap to Earnings|Forward P/E Multiple Oramed Pharmaceuticals Inc.|ORMP - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio ORMP|ORMP - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Oramed Pharmaceuticals|ORMP - Earnings per one share for the last 12 months|Quarterly EPS earnings growth oramed.com|ORMP - Earnings per share increase in current year|Earnings growth forecast for next year Oramed Pharmaceuticals
Initial company analysis:ORMP (Oramed Pharma)
Automating the synthesis of oral insulin at Oramed Pharmaceuticals (ORMP) requires significant capital expenditures, making the business's EV/EBITDA multiple chart critical for valuing the company relative to its operating profit before interest and taxes. This indicator allows investors to determine the asset's degree of overvaluation, accounting for debt load, and to assess business resilience during prolonged clinical trials.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MannKind Corp (MNKD) - Company Value to EBITDA|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation PCRX (Pacira Corp)|SPRY: EV/EBITDA Multiple|theravance.com (TBPH) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aquestive Therapeutics, Inc.|Enterprise Value to EBITDA Ratio scPharma (SCPH)|EV/EBITDA Multiple TECX|TNXP - Company Value to EBITDA|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|EPRX: Enterprise Value to Operating Income Before Depreciation|BHST: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation EXOZ (Invizyne Technologies)|enterabio.com (ENTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio HYFT (MindWalk Therapeutics)|ABVC (ABVC BioPharma) - EV/EBITDA Multiple|CPIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple QNTM|EV/EBITDA Multiple FibroGen Inc (FGEN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|Business Value to Operating Income Before Depreciation RANI|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Rallybio Corporation (RLYB) - Enterprise Value to EBITDA Ratio|LEXX: EV/EBITDA Multiple|Pulmatrix Inc (PULM) - EV/EBITDA Multiple|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Aptorum (APM)|EV/EBITDA Multiple LYRA|IBO - Company Value to EBITDA|TNF Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple cbdMD Inc. YCBD|PRFX: Enterprise Value to EBITDA Ratio|Altamira Therapeutics - Enterprise Value to Operating Income Before Depreciation Ratio|LIPO: EV/EBITDA Multiple|OPTN - Total Company Value to Operating Income Before Depreciation Ratio|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Procaps Group (PROC)|EV/EBITDA Multiple PTPI|EV/EBITDA Multiple Qilian International Corp (QLI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|tffpharma.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
